First-in-Human trial tests engineered immune cells against tough liver cancer
NCT ID NCT06757881
Summary
This is an early-phase study testing the safety of a new cell therapy for advanced liver cancer that has come back or stopped responding to standard treatments. Researchers will collect a patient's own immune cells, modify them in a lab to target a protein called IL1RAP found on cancer cells, and then infuse them back into the patient. The main goal is to find a safe dose and understand the side effects, while also checking for early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Affiliated to Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.